Avicanna's Q2 2025 Performance Overview
Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is excited to share the results of its second quarter in 2025. The company continues to shine in the biopharmaceutical landscape, focusing on the development and commercialization of innovative plant-derived cannabinoid-based products.
Management Insights and Growth Strategies
As emphasized by CEO Aras Azadian, Q2 was a noteworthy period for Avicanna, marked by advancements in their product pipeline and strengthened relationships with the Canadian medical community. These developments led to growth across multiple commercial channels and a robust portfolio that has maintained high margins. Their impressive achievement of positive adjusted EBITDA in the first half of the year underscores their focus on financial discipline and operational efficiency, setting a solid foundation for both domestic and international market expansion.
Financial Highlights of Q2 2025
During the second quarter, Avicanna reported a revenue of $6.16 million, bringing the total for the six-month period to $12.48 million. This reflects a slight growth of 1% quarter-over-quarter but a decrease of 1% overall compared to the same timeframe in the previous year.
Gross Profit and Margins
Gross profit showcased impressive results, reaching $3.13 million for Q2, while the six-month total stood at $6.73 million. This resulted in gross margins of 51% for Q2 and 54% over the six-month period, up from 47% in the prior year. The surge in margins can be attributed to increased service and licensing revenue, particularly from international markets.
Adjusted EBITDA Outcomes
Adjusted EBITDA reflected a loss of $0.25 million for the second quarter, yet the six-month period showed a gain of $0.18 million. This signifies a remarkable recovery compared to losses recorded in 2024, emphasizing reduced operational costs and better margins as key factors in this turnaround.
Corporate Highlights and Innovations
Avicanna continued to push boundaries in Q2 with significant advancements in their Canadian commercial landscape.
Commercial Success Stories
The second quarter ended with the company managing 50 commercial SKUs and 147 listings. This marked a 19% growth in total SKUs and a 9% increase in listings from Q1. Additionally, Avicanna sold 50,789 units during this quarter, reflecting a 21% rise compared to the second quarter of 2024.
Clinical Innovations
Avicanna also announced its sponsorship of a groundbreaking pilot Phase II clinical study on osteoarthritis pain. Led by Dr. Hance Clarke at the University Health Network, this study aims to evaluate the efficacy of Avicanna’s proprietary oral cannabis extracts as a treatment option. This initiative marks the company's first multi-center RCT, funded by a grant from the Canadian Institutes of Health Research.
Educational Efforts
A significant symposium focusing on cannabinoid-based medicine was hosted at the MaRS Discovery District, bringing together healthcare professionals to discuss the latest R&D, medical applications, and the practical integration of cannabinoid treatments. This event illustrates Avicanna’s commitment to advancing knowledge and practices in the medical community.
New Patent for Skin Health
Further enhancing its intellectual property portfolio, Avicanna secured a new patent from the US Patent and Trademark Office for topical cannabinoid compositions aimed at improving skin health. This patent encompasses a gel formulation essential for treating issues like acne and wrinkles, showcasing the potential to address a variety of dermatological conditions.
About Avicanna
Avicanna is a dedicated biopharmaceutical company specializing in cannabinoid-based products and formulations tailored for the medical and pharmaceutical markets worldwide. With a strong R&D foundation, the company has successfully introduced over thirty proprietary products and supports multiple commercial ventures.
Product Offerings and Platforms
The RHO Phyto™ medical cannabis formulary presents a wide array of products including oral, topical, and transdermal treatments with carefully crafted cannabinoid ratios, supported by extensive education for patients and practitioners.
Patient-Centric Initiatives
MyMedi.ca represents Avicanna’s efforts to enhance the medical cannabis experience for patients, providing a wealth of resources and support tailored to diverse patient needs.
Research and Development Pipeline
Leveraging a comprehensive scientific platform, Avicanna is advancing a pipeline of cannabinoid-based candidates targeting unmet needs in dermatology, chronic pain, and neurological disorders.
Active Pharmaceutical Ingredients
Through its subsidiary, Santa Marta Golden Hemp SAS, Avicanna supplies high-quality CBD, THC, and CBG to global partners, ensuring reliable inputs for its wide-reaching consumer and pharmaceutical networks.
Frequently Asked Questions
What are the key financial achievements of Avicanna in Q2 2025?
Avicanna reported a revenue of $6.16 million for Q2 2025 with impressive gross margins of 51%, a significant increase from prior years.
What clinical studies is Avicanna sponsoring?
The company is sponsoring a pilot Phase II clinical study on osteoarthritis pain led by Dr. Hance Clarke, focusing on the effectiveness of their proprietary cannabis extracts.
How many commercial SKUs does Avicanna have?
As of Q2 2025, Avicanna has 50 commercial SKUs and 147 listings in Canada, reflecting significant growth in their product portfolio.
What is the RHO Phyto™ medical cannabis formulary?
This formulary includes a diverse range of proprietary cannabinoid products designed to meet various patient needs through different delivery methods.
How does MyMedi.ca support patients?
MyMedi.ca provides a comprehensive medical cannabis care platform that offers resources, education, and support programs for patients across different demographics.
